hMSTN
品系全名
C57BL/6JSmo-Mstntm(hMSTN)Smoc
目录号
NM-HU-230106
品系状态
活体
基因信息
基因名
Mstn
品系描述
验证数据

Fig.1 Detection of MSTN expression in mammary gland by RT-PCR.
Wild type: only one band at 135 bp with primers F1/R1(mMstn);
Homozygous: only one band at 291 bp with primers F2/R2(hMSTN).
Abbr. M, DNA marker; HO, homozygous; WT, wild type.

Fig.2 Detection of hMSTN(A) and mMSTN(B) expression in serum by ELISA (female, 7-8wks, n=3).
Abbr. HO, homozygous; WT, wild type.
Note. The Human MSTN ELISA Kit cross-reacted with mouse MSTN and humanized MSTN.

Fig.3 In vivo efficacy of a human MSTN-targeting siRNA drug in hMSTN mice (Data from a collaborator).
Homozygous hMSTN mice were randomly divided into two groups (female, 7 weeks old, n=5/group). Mice were administered a siRNA drug, containing the sequence from AD06569 drug. Serum MSTN levels were detected before and after dosing in hMSTN mice. Compared to the vehicle group, the siRNA treatment group demonstrated a significant decrease in serum MSTN levels. (Mean±SEM. Unpaired t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

Fig.4 The efficacy evaluation of test articles in hMSTN mouse model (Male, 6-week-old, n=7).

Fig.5 The efficacy evaluation of test articles in hMSTN mouse model. Both MSTN receptor antibodies and MSTN antibodies can increase muscle mass and reduce fat mass in hMSTN mice (Male, 6-week-old, n=7).

Fig.6 Pharmacodynamic validation in the HFD-Induced hMSTN Obese Mouse Model. Body weight changes and food intake measurement of Semaglutide combined with MSTN (GDF8) antibody and MSTN receptor antibody in hMSTN mice fed a high‑fat diet (Male, 6-8-week-old).

Fig.7 Body composition of the HFD-Induced hMSTN Obese Mouse Model. Detection of fat and muscle changes in hMSTN mice fed a high‑fat diet following combined administration of Semaglutide, MSTN (GDF8) antibody, and MSTN receptor antibody (Male, 6-8-week-old).

Fig.8 Fasting blood glucose and tissue weight of the HFD-Induced hMSTN Obese Mouse Model. Detection of various tissue indices in hMSTN mice fed a high‑fat diet following combined administration of Semaglutide, MSTN (GDF8) antibody, and MSTN receptor antibody (Male, 6-8-week-old).
你也可能感兴趣
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
查看Workshop:Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
查看Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
查看
